OBJECTIVES: Treated HIV-1-infected patients with lipodystrophy often develop insulin resistance and proatherogenic dyslipidaemia. Zinc alpha-2 glycoprotein (ZAG) is a recently characterized adipokine which has been shown to be involved in the development of obesity and metabolic syndrome in uninfected subjects. We assessed the relationship between circulating ZAG levels and metabolic derangements in HIV-1-infected patients receiving antiretroviral drugs. METHODS: Plasma ZAG levels were assessed in 222 individuals: 166 HIV-1-infected patients treated with antiretroviral drugs (77 with lipodystrophy and 89 without lipodystrophy) and 56 uninfected controls. Plasma ZAG levels were assessed by enzyme-linked immunosorbent assay (ELISA) and were correlated with fat distribution abnormalities and metabolic parameters. RESULTS: HIV-1-infected patients had lower plasma ZAG levels compared with uninfected controls (P < 0.001). No differences were found in ZAG plasma levels according to the presence of lipodystrophy, components of the metabolic syndrome or type of antiretroviral treatment regimen. Circulating ZAG levels were strongly determined by high-density lipoprotein cholesterol (HDLc) in men (B = 0.644; P < 0.001) and showed a positive correlation with total cholesterol (r = 0.312; P < 0.001) and HDLc (r = 0.216; P = 0.005). CONCLUSIONS: HIV-1-infected patients have lower plasma ZAG levels than uninfected controls. In infected patients, plasma ZAG levels are in close relationship with total cholesterol and HDLc.
OBJECTIVES: Treated HIV-1-infectedpatients with lipodystrophy often develop insulin resistance and proatherogenic dyslipidaemia. Zinc alpha-2 glycoprotein (ZAG) is a recently characterized adipokine which has been shown to be involved in the development of obesity and metabolic syndrome in uninfected subjects. We assessed the relationship between circulating ZAG levels and metabolic derangements in HIV-1-infectedpatients receiving antiretroviral drugs. METHODS: Plasma ZAG levels were assessed in 222 individuals: 166 HIV-1-infectedpatients treated with antiretroviral drugs (77 with lipodystrophy and 89 without lipodystrophy) and 56 uninfected controls. Plasma ZAG levels were assessed by enzyme-linked immunosorbent assay (ELISA) and were correlated with fat distribution abnormalities and metabolic parameters. RESULTS:HIV-1-infectedpatients had lower plasma ZAG levels compared with uninfected controls (P < 0.001). No differences were found in ZAG plasma levels according to the presence of lipodystrophy, components of the metabolic syndrome or type of antiretroviral treatment regimen. Circulating ZAG levels were strongly determined by high-density lipoprotein cholesterol (HDLc) in men (B = 0.644; P < 0.001) and showed a positive correlation with total cholesterol (r = 0.312; P < 0.001) and HDLc (r = 0.216; P = 0.005). CONCLUSIONS:HIV-1-infectedpatients have lower plasma ZAG levels than uninfected controls. In infectedpatients, plasma ZAG levels are in close relationship with total cholesterol and HDLc.
Authors: Sidgi Syed Anwer Hasson; Mohammed Saeed Al-Balushi; Muzna Hamed Al Yahmadi; Juma Zaid Al-Busaidi; Elias Antony Said; Mohammed Shafeeq Othman; Talal Abdullah Sallam; Mohammed Ahmad Idris; Ali Abdullah Al-Jabri Journal: Asian Pac J Trop Biomed Date: 2014-08
Authors: Gerard Bryan Gonzales; James M Njunge; Bonface M Gichuki; Bijun Wen; Isabel Potani; Wieger Voskuijl; Robert H J Bandsma; James A Berkley Journal: Sci Rep Date: 2020-07-08 Impact factor: 4.379
Authors: Inga Sörensen-Zender; Jan Beneke; Bernhard M W Schmidt; Jan Menne; Hermann Haller; Roland Schmitt Journal: BMC Nephrol Date: 2013-07-12 Impact factor: 2.388
Authors: Jing Long; Robindra Basu Roy; Yanjia J Zhang; Robin Antrobus; Yuxian Du; Duncan L Smith; Michael P Weekes; Babak Javid Journal: Front Microbiol Date: 2016-07-12 Impact factor: 5.640